Vioxx And Bextra Get Split Votes From FDA Cmte. On Marketing

Vote slightly favors return of Vioxx to the market and continued marketing of Bextra. "Black box" warning on cardiovascular risk is recommended for COX-2s, including Pfizer's Celebrex. Restriction or banning of direct-to-consumer advertising also is advised by committee members.